



DO BREAST MICROCALCIFICATIONS IMMORTALISE TISSUE PATHOLOGY? - A PRELIMINARY STUDY





Sarah Gosling¹, Robert Scott¹, Charlene Greenwood², Pascaline Bouzy³, Jayakrupakar Nallala³, Iain D Lyburn⁴, Nicholas Stone³ & Keith Rogers¹.

¹Cranfield Forensic Institute, Cranfield University, Shrivensham, UK

²School of Chemical and Physical Sciences, Keele University, Keele, UK

³School of Physics and Astronomy, Exeter University, Exeter, UK

⁴Thirlestaine Breast Centre, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK



References

- Wopenka B., Pasteris JD. Materials Science and Engineering: C. April 2005; 25(2): 131–143.
- Baker R., Rogers KD., Shepherd N., Stone N. British Journal of Cancer. Nature Publishing Group; 2010; 103(7): 1034–1039.

Funding Acknowledgements

CRUK Grand Challenge DCIS PRECISION
An international conglomerate working to identify novel biomarkers for DCIS which will progress into or recur as invasive carcinoma ref. C38317/A24043

MRC Immortalisation of Breast Pathology
An MRC funded project to identify crystallographic differences between calcifications found in a wide range of breast tissue pathologies

Conclusions

- > Lower total carbonate leads to larger crystallite size with increasing malignancy²
- > An increasing B/A type ratio with malignancy leads to an increased strain in invasive calcifications
- > Tissue pathology governs calcification formation mechanisms